Literature DB >> 9916992

The role of ATM in DNA damage responses and cancer.

C E Canman1, D S Lim.   

Abstract

Ataxia-telangiectasia (AT) is a complex, autosomal recessive disorder characterized by cerebellar ataxia, believed to result from progressive neurodegeneration, and telangiectasia, dilation of blood vessels within the eyes and parts of the facial region. AT patients suffer from recurrent infections caused by both cellular and humoral immune deficiencies and as a population, are significantly predisposed to cancer, particularly lymphomas and leukemias. Early attempts at treating these malignancies with radiotherapy revealed another hallmark of AT, a profound hypersensitivity to the cytotoxic effects of ionizing radiation (IR) which is recapitulated at the cellular level in culture. Predisposition to cancer and radiosensitivity observed in AT has been linked to chromosomal instability, abnormalities in genetic recombination, and defective signaling to programmed cell death and several cell cycle checkpoints activated by DNA damage. These earlier observations predicted that the gene defective in AT may encode a protein which plays a crucial role in sensing DNA damage and transducing signals that promote cell survival. Through the combined efforts of linkage analysis and positional cloning, a single gene was identified on chromosome 11q22-33 by Shiloh and colleagues and was found to be mutated in all four complementation groups previously characterized in cell lines derived from AT patients (Savitsky et al., 1995a,b). The predicted ATM gene product shows considerable homology to an emerging family of high molecular weight, phosphatidylinositol-3 kinase (PI-3 K)-related proteins involved in eukaryotic cell cycle control, DNA repair, and DNA recombination (Zakian, 1995). This landmark discovery has triggered a resurgence of biochemical and genetic studies focusing on ATM function which has brought forth insights regarding ATM activity and its role in DNA damage signaling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9916992     DOI: 10.1038/sj.onc.1202577

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  Immunoglobulin class switch recombination: will genetics provide new clues to mechanism?

Authors:  N Maizels
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

Review 3.  Cellular senescence in cancer treatment: friend or foe?

Authors:  Pascal Kahlem; Bernd Dörken; Clemens A Schmitt
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.

Authors:  Yun-Ling Zheng; Christopher A Loffredo; Anthony J Alberg; Zhipeng Yu; Raymond T Jones; Donna Perlmutter; Lindsey Enewold; Mark J Krasna; Rex Yung; Peter G Shields; Curtis C Harris
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

5.  Classic ataxia-telangiectasia in a Sudanese boy: Case report and review of the literature.

Authors:  Haydar El Hadi Babikir
Journal:  Sudan J Paediatr       Date:  2011

6.  A plausible model for the digital response of p53 to DNA damage.

Authors:  Lan Ma; John Wagner; John Jeremy Rice; Wenwei Hu; Arnold J Levine; Gustavo A Stolovitzky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

7.  ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.

Authors:  Mark A Gregory; Angelo D'Alessandro; Francesca Alvarez-Calderon; Jihye Kim; Travis Nemkov; Biniam Adane; Andrii I Rozhok; Amit Kumar; Vijay Kumar; Daniel A Pollyea; Michael F Wempe; Craig T Jordan; Natalie J Serkova; Aik Choon Tan; Kirk C Hansen; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

8.  Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study.

Authors:  Yun-Ling Zheng; Ourania Kosti; Christopher A Loffredo; Elise Bowman; Leah Mechanic; Donna Perlmutter; Raymond Jones; Peter G Shields; Curtis C Harris
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

9.  HIPK1 drives p53 activation to limit colorectal cancer cell growth.

Authors:  Christophe Rey; Isabelle Soubeyran; Isabelle Mahouche; Stephane Pedeboscq; Alban Bessede; François Ichas; Francesca De Giorgi; Lydia Lartigue
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

10.  Functional dissection of Caenorhabditis elegans CLK-2/TEL2 cell cycle defects during embryogenesis and germline development.

Authors:  Sandra C Moser; Sophie von Elsner; Ingo Büssing; Arno Alpi; Ralf Schnabel; Anton Gartner
Journal:  PLoS Genet       Date:  2009-04-10       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.